Claims
- 1. The use of compositions useful in the inhibition of cancerous cell proliferation selected from a group consisting of:
the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 3, specifically excluding any claim to 2-methyloxyestradiol; the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 3; the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 3; the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 4; the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 1; the 2-ethyl substituted molecule identified as analogue 14 in FIG. 1; and the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 2.
- 2. A method for inhibiting cancerous cell proliferation comprising the steps of:
selecting a composition from the group consisting of the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 3, specifically excluding any claim to 2-methyloxyestradiol, the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 3, the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 3, the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 4, the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 1, the 2-ethyl substituted molecule identified as analogue 14 in FIG. 1, or the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 2; and administering said composition to cells in which is identified suspected cancer cells.
- 3. The method of claim 2 wherein said suspected cancer cells are brain cancer cells.
- 4. The method of claim 2 wherein said suspected cancer cells are nervous system cancer cells.
- 5. The method of claim 2 wherein said suspected cancer cells are brain cancer cells and nervous system cancer cells.
- 6. The method of claim 2 wherein said suspected cancer cells are prostate cancer cells.
- 7. A composition for application to cancerous cells consisting in active constituents substantially of one or more agents chosen from the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 3, specifically excluding any claim to 2-methyloxyestradiol, the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 3, the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 3, the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 4, the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 1, the 2-ethyl substituted molecule identified as analogue 14 in FIG. 1, or the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 2.
- 8. The method of claim 8 wherein said suspected cancer cells are brain cancer cells.
- 10. The method of claim 8 wherein said suspected cancer cells are nervous system cancer cells.
- 11. The method of claim 8 wherein said suspected cancer cells are brain cancer cells and nervous system cancer cells.
- 12. The method of claim 8 wherein said suspected cancer cells are prostate cancer cells.
CITATION TO PRIOR APPLICATION
[0001] This is a continuation-in-part with respect to U.S. application Ser. No. 09/527283, filed Mar. 17, 2000 from which priority is claimed under 35 U.S.C. §120 and under provisions of the Patent Cooperation Treaty.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09527283 |
Mar 2000 |
US |
Child |
09777151 |
Feb 2001 |
US |